Avicanna anuncia el lanzamiento en Canadá de una formulación de su propiedad con un 10% de CBD (sin THC)
March 28, 2024 07:30 ET
|
Avicanna Inc.
La formulación oral con un 10% de CBD (sin THC) se comercializa como RHO Phyto Micro Drop 100 en Canadá. RHO Phyto Micro Drop 100 está disponible exclusivamente en MyMedi.ca. TORONTO, March 28,...
Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation
March 27, 2024 08:02 ET
|
Avicanna Inc.
The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in Canada RHO Phyto Micro Drop 100 is available exclusively at MyMedi.ca. TORONTO, March 27, 2024 (GLOBE...
Avicanna To Hold Full Year 2023 Earnings Conference Call
March 26, 2024 07:30 ET
|
Avicanna Inc.
TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna obtiene su primer registro de medicamento para indicación específica con Trunerox™
February 29, 2024 08:00 ET
|
Avicanna Inc.
TORONTO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" o la "Empresa) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) una empresa biofarmacéutica centrada en el desarrollo, fabricación y...
Avicanna Hosts Symposium on Cannabinoid-based Medicine
February 29, 2024 07:30 ET
|
Avicanna Inc.
TORONTO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Announces New Research Collaboration with a Multi-national European-based Pharmaceutical Company
February 15, 2024 07:30 ET
|
Avicanna Inc.
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™
February 13, 2024 07:30 ET
|
Avicanna Inc.
TORONTO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company
February 05, 2024 07:50 ET
|
Avicanna Inc.
Exclusive supply agreement for two of Avicanna’s proprietary topical products in the European region Right of first refusal agreement for the Avicanna’s SEDDs capsules in the European region ...
Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil
January 30, 2024 07:30 ET
|
Avicanna Inc.
TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Announces Closing of Non-Brokered Private Placement
December 04, 2023 17:00 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...